Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is listed today as Relay Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2024 | $30 M | Private placement after listing | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Relay Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2024).
SEC Form D · Jan 2024
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jan 2024
That is all the official record says: Relay Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Relay Therapeutics, Inc. are on record.
Investors#
13 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alexandria Venture Investments, LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Alexis Borisy | Person | not stated | not stated | Held Series C preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Mark Murcko | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Picularium, LLC | Other | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| SB Investment Advisers (UK) LTD | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Softbank Vision Fund (aiv M2) L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| SVF Pauling (Cayman) Ltd | Company | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Third Rock Ventures GP III, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Third Rock Ventures GP IV, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Third Rock Ventures III, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Third Rock Ventures IV, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| TRV GP III, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Trv Gp Iv, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Relay Therapeutics, Inc. shares, as of Sep 30, 2026.
- FMR LLC$438 M10.97%
- SB Investment Advisers (UK) LTD$395 M9.91%
- T. Rowe Price Investment Management, Inc.$323 M8.09%
- BlackRock, Inc.$301 M7.56%
- Casdin Capital, LLC$289 M7.26%
- Perceptive Advisors LLC$230 M5.76%
- Commodore Capital LP$217 M5.43%
- State Street Corp$165 M4.14%
- Vanguard Capital Management LLC$163 M4.08%
- Nextech Invest Ltd.$122 M3.07%
- Price T Rowe Associates Inc /MD/$120 M3.00%
- Bellevue Group AG$112 M2.80%
- Geode Capital Management, LLC$92 M2.31%
- Alliancebernstein L.P.$71 M1.77%
- TCG Crossover Management, LLC$68 M1.71%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Brian K. Adams | Executive officer | Jan 2024 |
| Donald A. Bergstrom | Executive officer | Jan 2024 |
| Peter A. Rahmer | Executive officer | Jan 2024 |
| Sanjiv K. Patel | Executive officer | Jan 2024 |
| Thomas A. Catinazzo | Executive officer | Jan 2024 |
| Alexis A. Borisy | Director | Jan 2024 |
| Douglas S. Ingram | Director | Jan 2024 |
| Jami S. Rubin | Director | Jan 2024 |
| Laura S. Shawver | Director | Jan 2024 |
| Linda A. Hill | Director | Jan 2024 |
| Mark S. Murcko | Director | Jan 2024 |
| Sanjiv K. Patel | Director | Jan 2024 |
| Sekar S. Kathiresan | Director | Jan 2024 |
About
Company in Cambridge, United States.
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.